Imaging the L-Type Amino Acid Transporter-1 (LAT1) with Zr-89 ImmunoPET

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Ikotun, Oluwatayo F ^a   Marquez, Bernadette V ^a   Huang, Chaofeng ^a   Masuko, Kazue ^b   Daiji, Miyamoto ^b   Masuko, Takashi ^b   McConathy, Jonathan ^a   Lapi, Suzanne E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KINKI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID TRANSPORTER; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZIRCONIUM DEFEROXAMINE AMINO ACID TRANSPORTER 1 ANTIBODY ZR 89;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CANCER DIAGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG SCREENING; DRUG UPTAKE; IMMUNOPOSITRON EMISSION TOMOGRAPHY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; SENSITIVITY AND SPECIFICITY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL TRANSFORMATION, NEOPLASTIC; HCT116 CELLS; HELA CELLS; HUMANS; ISOTOPE LABELING; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RATS; ZIRCONIUM;

EID: 84885467879     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077476     Document Type: Article

References (41)

1. Ohno Y, Suda K, Masuko K, Yagi H, Hashimoto Y, et al. (2008) Production and characterization of highly tumor-specific rat monoclonal antibodies recognizing the extracellular domain of human L-type amino-acid transporter 1. Cancer Sci 99: 1000-1007. doi:10.1111/j.1349-7006.2008.00770.x. PubMed: 18294274.
2. Fuchs BC, Bode BP, (2005) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15: 254-266. doi:10.1016/j.semcancer.2005.04.005. PubMed: 15916903.
3. Kanai Y, Segawa H, Miyamoto KI, Uchino H, Takeda E, et al. (1998) Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98). J Biol Chem 273: 23629-23632. doi:10.1074/jbc.273.37.23629. PubMed: 9726963.
4. Teixeira S, Di Grandi S, Kühn LC, (1987) Primary structure of the human 4F2 antigen heavy chain predicts a transmembrane protein with a cytoplasmic NH2 terminus. J Biol Chem 262: 9574-9580. PubMed: 3036867.
5. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, et al. (2001) Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochimica et Biophysica Acta (BBA)- Biomembranes 1514: 291-302. doi:10.1016/S0005-2736(01)00384-4. PubMed: 11557028.
6. Jewell JL, Guan KL, (2013) Nutrient signaling to mTOR and cell growth. Trends Biochem Sci, 38: 233-42. PubMed: 23465396.
7. Fan X, Ross DD, Arakawa H, Ganapathy V, Tamai I, et al. (2010) Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: a possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. Biochem Pharmacol 80: 811-818. doi:10.1016/j.bcp.2010.05.021. PubMed: 20510678.
8. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, et al. (2009) Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 136: 521-534. doi:10.1016/j.cell.2008.11.044. PubMed: 19203585.
9. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, et al. (2009) Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci 100: 248-254. PubMed: 19068093.
10. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, et al. (2008) Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98: 742-748. doi:10.1038/sj.bjc.6604235. PubMed: 18253116.
11. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, et al. (2009) L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 59: 7-18. doi:10.1111/j.1440-1827.2008.02319.x. PubMed: 19121087.
12. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, et al. (2006) L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119: 484-492. doi:10.1002/ijc.21866. PubMed: 16496379.
13. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, et al. (2006) F-FDOPA PET imaging of brain tumors: comparison study with 18 F-FDG PET and evaluation of diagnostic accuracy 18. J Nucl Med 47: 904-911. PubMed: 16741298.
14. Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, et al. (2009) Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol 36: 779-787. doi:10.1016/j.nucmedbio.2009.05.005. PubMed: 19720290.
15. Pauleit D, Floeth F, Tellmann L, Hamacher K, Hautzel H, et al. (2004) Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors. J Nucl Med 45: 374-381. PubMed: 15001676.
16. Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, et al. (2011) An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases. Int J Radiat Oncol Biol Phys 81: 1049-1058. doi:10.1016/j.ijrobp.2010.07.002. PubMed: 21570201.
17. Watanabe H, Inoue T, Shinozaki T, Yanagawa T, Ahmed AR, et al. (2000) PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET. Eur J Nucl Med 27: 1509-1517. doi:10.1007/s002590000344. PubMed: 11083540.
18. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, et al. (2001) Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 42: 432-445. PubMed: 11337520.
19. Youland RS, Kitange GJ, Peterson TE, Pafundi DH, Ramiscal JA, et al. (2013) The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neuro Oncol 111: 11-18. doi:10.1007/s11060-012-0986-1. PubMed: 23086431.
20. Lahoutte T, Caveliers V, Camargo SM, Franca R, Ramadan T, et al. (2004) SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med 45: 1591-1596. PubMed: 15347729.
21. Haase C, Bergmann R, Fuechtner F, Hoepping A, Pietzsch J, (2007) L-Type Amino Acid Transporters LAT1 and LAT4 in Cancer: Uptake of 3-O-Methyl-6- 18F-Fluoro-l-Dopa in Human Adenocarcinoma and Squamous Cell Carcinoma In Vitro and In Vivo. J Nucl Med 48: 2063-2071. doi:10.2967/jnumed.107.043620. PubMed: 18056335.
22. Ohkawa M, Ohno Y, Masuko K, Takeuchi A, Suda K, et al. (2011) Oncogenicity of L-type amino-acid transporter 1 (LAT1) revealed by targeted gene disruption in chicken DT40 cells: LAT1 is a promising molecular target for human cancer therapy. Biochem Biophys Res Commun 406: 649-655. doi:10.1016/j.bbrc.2011.02.135. PubMed: 21371427.
23. Masuko T, Ohno Y, Masuko K, Yagi H, Uejima S, et al. (2011) Towards therapeutic antibodies to membrane oncoproteins by a robust strategy using rats immunized with transfectants expressing target molecules fused to green fluorescent protein. Cancer Sci 102: 25-35. doi:10.1111/j.1349-7006.2010.01741.x. PubMed: 21040216.
24. Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, et al. (2010) Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc 5: 739-743. doi:10.1038/nprot.2010.13. PubMed: 20360768.
25. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, et al. (2010) 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51: 1293-1300. doi:10.2967/jnumed.110.076174. PubMed: 20660376.
26. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, et al. (2010) Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87: 586-592. doi:10.1038/clpt.2010.12. PubMed: 20357763.
27. Chang AJ, De Silva RA, Lapi SE, (2013) Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. Mol Imaging 12: 17-27. PubMed: 23348788.
28. Holland JP, Sheh Y, Lewis JS, (2009) Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol 36: 729-739. doi:10.1016/j.nucmedbio.2009.05.007. PubMed: 19720285.
29. Zuhayra M, Alfteimi A, Forstner CV, Lützen U, Meller B, et al. (2009) New approach for the synthesis of [18F]fluoroethyltyrosine for cancer imaging: Simple, fast, and high yielding automated synthesis. Bioorganic & J Med Chem 17: 7441-7448.
30. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr., (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72: 77-89. doi:10.1016/0022-1759(84)90435-6. PubMed: 6086763.
31. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJP, et al. (2011) Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors. Cancer Res 71: 2250-2259. doi:10.1158/0008-5472.CAN-10-2277. PubMed: 21406401.
32. Dijkers EC, Kosterink JG, Rademaker AP, Perk LR, van Dongen GA, et al. (2009) Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50: 974-981. doi:10.2967/jnumed.108.060392. PubMed: 19443585.
33. Nayak TK, Garmestani K, Milenic DE, Brechbiel MW, (2012) PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab. J Nucl Med 53: 113-120. doi:10.2967/jnumed.111.094169. PubMed: 22213822.
34. Abou DS, Ku T, Smith-Jones PM, (2011) In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol 38: 675-681. doi:10.1016/j.nucmedbio.2010.12.011. PubMed: 21718943.
35. Solingapuram Sai KK, Huang C, Yuan L, Zhou D, Piwnica-Worms D, et al. (2013) 18F-AFETP, 18F-FET, and 18F-FDG Imaging of Mouse DBT Gliomas. J Nucl Med 54: 1120-1126. doi:10.2967/jnumed.112.113217. PubMed: 23650628.
36. Lee TS, Ahn SH, Moon BS, Chun KS, Kang JH, et al. (2009) Comparison of 18F-FDG, 18F-FET and 18F-FLT for differentiation between tumor and inflammation in rats. Nucl Med Biol 36: 681-686. doi:10.1016/j.nucmedbio.2009.03.009. PubMed: 19647174.
37. Spaeth N, Wyss MT, Weber B, Scheidegger S, Lutz A, et al. (2004) Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. J Nucl Med 45: 1931-1938. PubMed: 15534065.
38. Jones AR, Shusta EV, (2007) Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 24: 1759-1771. doi:10.1007/s11095-007-9379-0. PubMed: 17619996.
39. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, et al. (2011) Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3: 84ra44. PubMed: 21613623.
40. Boado RJ, Zhang Y, Pardridge WM, (2007) Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier. Biotechnol Bioeng 97: 1376-1386. doi:10.1002/bit.21369. PubMed: 17286273.
41. Mishra V, Mahor S, Rawat A, Gupta PN, Dubey P, et al. (2006) Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 14: 45-53. doi:10.1080/10611860600612953. PubMed: 16603451.